Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.

• Status: RECRUITING
• Trial end date: 2030-01-01

Summary

PANThEON is a randomized, open-label, multicenter phase III trial aimed at comparing the switch maintenance with gemcitabine plus nab-paclitaxel (ARM B) versus mFOLFIRINOX continuation (ARM A) in terms of overall survival (OS) in patients with unresectable LAD or mPDAC without disease progression following 3 months of induction mFOLFIRINOX triplet chemotherapy.

• Phase: PHASE3

Details

• Lead Sponsor: Gruppo Oncologico del Nord-Ovest
• Collaborator: Rising Tide Foundation
• Treatments: 130-nm albumin-bound paclitaxel; Fluorouracil; Gemcitabine; Irinotecan; Leucovorin; Oxaliplatin